Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017698823> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- W2017698823 endingPage "0371" @default.
- W2017698823 startingPage "0371" @default.
- W2017698823 abstract "Poly(ADP-ribose) is synthesized by poly(ADP-ribose) polymerase (PARP) from β-nicotinamide adenine dinucleotide (NAD + ). It is mainly degraded by poly(ADP-ribose) glycohydrolase (PARG). The expanding family of PARP currently consists of PARP 1 - 3 , vPARP, Tankyrase 1 - 2 , 2 , and more members are being characterized. Similarly, the PARG family awaits more homologs to be identified. PARP 1 , which is activated by DNA damage, accounts for > 95% poly(ADP-ribose) synthesis. Poly(ADP-ribose) has a half-life of < 1 min in vivo, due to its immediate degradation by PARG. The PARP 1 /PARG cycle results in depletion of NAD + and ATP, which can be prevented by inhibiting PARP 1 or PARG. After PARP 1 was implicated in facilitating DNA repair, pharmaceutical companies began developing PARP inhibitors as potentiators to enhance chemotherapy and radiation therapy in cancers. Recent studies using PARP 1 knockout mice and PARP inhibitors validated targeting the poly(ADP-ribose) pathway for ameliorating ischemia injury and abating inflammation. Multiple families of PARP and PARG inhibitors have been identified. A number of these inhibitors have demonstrated efficacy in animal models of cerebral ischemia, traumatic brain injury, Parkinson's disease, myocardial ischemia, retinal ischemia, kidney ischemia, type 1 diabetes, septic shock, hemorrhagic shock, arthritis, inflammatory bowel disease, multiple sclerosis and potentiation of chemotherapy. The therapeutic utility of PARP inhibitors is expected to be studied soon in clinical trials." @default.
- W2017698823 created "2016-06-24" @default.
- W2017698823 creator A5068588397 @default.
- W2017698823 creator A5073501391 @default.
- W2017698823 date "2002-01-01" @default.
- W2017698823 modified "2023-10-17" @default.
- W2017698823 title "PARP and PARG as novel therapeutic targets" @default.
- W2017698823 doi "https://doi.org/10.1358/dof.2002.027.04.669101" @default.
- W2017698823 hasPublicationYear "2002" @default.
- W2017698823 type Work @default.
- W2017698823 sameAs 2017698823 @default.
- W2017698823 citedByCount "10" @default.
- W2017698823 crossrefType "journal-article" @default.
- W2017698823 hasAuthorship W2017698823A5068588397 @default.
- W2017698823 hasAuthorship W2017698823A5073501391 @default.
- W2017698823 hasConcept C182979987 @default.
- W2017698823 hasConcept C54355233 @default.
- W2017698823 hasConcept C552990157 @default.
- W2017698823 hasConcept C82381507 @default.
- W2017698823 hasConcept C86803240 @default.
- W2017698823 hasConceptScore W2017698823C182979987 @default.
- W2017698823 hasConceptScore W2017698823C54355233 @default.
- W2017698823 hasConceptScore W2017698823C552990157 @default.
- W2017698823 hasConceptScore W2017698823C82381507 @default.
- W2017698823 hasConceptScore W2017698823C86803240 @default.
- W2017698823 hasIssue "4" @default.
- W2017698823 hasLocation W20176988231 @default.
- W2017698823 hasOpenAccess W2017698823 @default.
- W2017698823 hasPrimaryLocation W20176988231 @default.
- W2017698823 hasRelatedWork W1991819215 @default.
- W2017698823 hasRelatedWork W1996031072 @default.
- W2017698823 hasRelatedWork W2021643429 @default.
- W2017698823 hasRelatedWork W2032673826 @default.
- W2017698823 hasRelatedWork W2063789556 @default.
- W2017698823 hasRelatedWork W2079384610 @default.
- W2017698823 hasRelatedWork W2094991297 @default.
- W2017698823 hasRelatedWork W2116804853 @default.
- W2017698823 hasRelatedWork W2367507890 @default.
- W2017698823 hasRelatedWork W3142312809 @default.
- W2017698823 hasVolume "27" @default.
- W2017698823 isParatext "false" @default.
- W2017698823 isRetracted "false" @default.
- W2017698823 magId "2017698823" @default.
- W2017698823 workType "article" @default.